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suitable for the majority of patients but not per se for the individual 
consulting patient.
Patients (or Materials) and Methods: Based on these challenges, 
emphasis of the course is put on attitude training. The good manage-
ment of a specific disease/condition comes in second line and is pri-
marily a way for attitude training. The main attitudes to learn are: [1] 
how to choose the most suitable drug for a target condition and [2] 
how to accommodate this choice to the individual patient? Students 
are trained in choosing drugs according to the “WHO guide to good 
prescribing’’ and in doing a consultation in a systematic way (the 
6-step approach). Key steps are the therapeutic goals and to check 
whether the first-choice treatment in the formulary/guideline would 
be suitable for the individual patient. The course consists of plenary 
lectures and tutorials prepared by homework. The expert clinician 
is asked to provide the knowledge of the diseases and therapeutic 
management during the plenary lectures. Tutorials are organized by 
the pharmacotherapy task force (PTF) in small groups (of ~15 stu-
dents) with the aim to analyze and process the patient cases using 
the 6-step approach. Pharmacotherapeutic competence is tested in a 
separate competence exam.
Results: Threats and opportunities for implementation: [1] Not all 
pharmacotherapy taught by expert clinicians was evidence based. 
This led to discussions with clinicians to implement evidence-based 
pharmacotherapy. When evidence for a treatment is poor or even 
absent, different schools may teach their own “expert opinion.” This 
is also explained to students and examples are given. [2] Not all teach-
ers were convinced of the utility of competence teaching and refused 
to participate or even disturbed the implementation. Therefore, a 
group of interested tutors has been trained in competence teaching, 
the PTF. [3] Students’ workload increased by the homework. Some 
students scored the pharmacotherapy tutorials very low, hoping to get 
rid of this extra homework. These complaints largely disappeared in 
the last year or during internships, when trained competences could 
be used in practice.
Conclusion: Students regularly get positive feedback from their train-
ers during internships and Erasmus exchanges about their acquired 
competence in pharmacotherapy.
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Introduction: There is global concern about the quality of prescrib-
ing training in medical schools and the rational prescribing skills of 
junior doctors. In the Faculty of Health Sciences, University of the 
Witwatersrand, curricular change sought to reduce the factual burden 
of learning and enhance evaluative capacities through the introduc-
tion of an integrated syllabus delivered via problem-based learning
Patients (or Materials) and Methods: Members of the graduating 
class of 2008 in the Faculty of Health Sciences, University of the 
Witwatersrand, were invited to participate in a directly administered 
cross-sectional survey using an Internet-administered questionnaire 
(assuring anonymous responses) through the Centre for Health 
Science Education (CHSE) electronic class noticeboard. In addition, 
their exit-level examination results were made available to calculate 
a “prescribing competence” mark.
Results: Despite the new curriculum, graduating students reported 
a lack of confidence to prescribe. To explore this finding, this paper 
analyzes prescribing competence in relation to Bernstein’s theoretical 
framework of the structure of knowledge. Prescribing is described 
as a regionalized skill in relation to several singular disciplines. For 
successful students, the disciplinary knowledge base necessary for 
rational prescribing decisions is a Bernsteinian vertical discourse with 
conceptual coherence. Other students, however, cannot distinguish 
beyond the context of each clinical problem presented, and their 
resultant learning is segmented and not transferrable. In addition, 
this contextual learning leads to a subjective increase in volume, since 
disciplinary knowledge is not incorporated into inclusive principles.
Conclusion: Thus, curricular components including problem-based 
learning and horizontal integration constrain epistemic access to the 
structure of rational prescribing knowledge for some students.
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Introduction: Drug fever is a disorder characterized by a febrile 
response coinciding temporally with the administration of drug in the 
absence of any other conditions that may cause the fever. It is impor-
tant for clinicians to suspect drugs as a cause of fevers of unknown 
origin because failure of prompt diagnosis can lead to prolonged 
hospital stay. Here we illustrate a case of drug-induced fever.
Patients (or Materials) and Methods: A 45-year-old woman had 
intermittent fever after an elective revision of her right knee hemiar-
throplasty. The initial suspicion was a partially treated septic arthri-
tis, and she was treated with a prolonged course of intravenous 
teicoplanin and oral rifampicin. Her fever persisted despite antibiot-
ics, prompting referral to our department.
Physical examination revealed a disproportionately well woman 
who was febrile (38.5). All her investigations showed no evidence of 
infection. After 5 days of antibiotic treatment, she remained febrile 
with a high C-reactive protein levels. The possibility of drug fever due 
to teicoplanin and/or rifampicin was discussed, and both drugs were 
discontinued. Upon discontinuation, her fever returned to normal 
and C-reactive protein levels normalized.
Results: Drug fever may have any pattern. The fever typically resolves 
within 48 to 72 hours, depending on the agent, its elimination rate, 
and the patient’s comorbidities. The single consistent characteristic 
of drug fever is the resolution of the fever when the responsible agent 
is stopped. In our case, the possibility of drug fever was considered 
because the patient appeared disproportionately well and was not 
mounting a tachycardic response to an infective process. Septic arthri-
tis was excluded with a negative synovial fluid aspirate. Endocarditis 
was excluded with a negative trans-thoracic echocardiogram. Blood 
culture and urine culture did not grow anything. Persistence of drug 
fever by teicoplanin has been described in various case reports. The 
fever occurred at doses of 0.12 mg/d and is prolonged with the long 
half-life of teicoplanin. Rifampicin is less likely to cause fever.
Conclusion: Drug fever is a common but often overlooked condition. 
Prompt diagnosis is important as it can obviate expensive diagnostic 
workup and inappropriate use of antimicrobial agents. It should be 
considered in cases when the patient is disproportionately well with 
no clear source of infection.
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Introduction: The “International Nonproprietary Name (INN) pre-
scribing project” in Belgium aimed to operationalize electronic INN 
prescribing for outpatient care in daily medical practice and medical 
informatics.
Patients (or Materials) and Methods: The operationalization process 
consisted of 3 phases: (1) expert consultation; (2) review by regula-
tory authorities; and (3) test phase with stakeholders and end-users.
Results: The INN prescribing project resulted in: (1) operational 
rules for electronic INN prescribing; (2) the classification of the thera-
peutic arsenal, according to the operational rules; and (3) a refer-
ence database to be implemented in commercial medical software. 
The operational rules for electronic INN prescribing define valid 
INN groups as sets of equivalent medicinal products, described by 3 
elements: the therapeutic moiety (the active part of the therapeutic 
ingredient) or combination of therapeutic moieties, the strength (with 
standardized denominators), and the method of administration (with 
simplified but standardized options). The operational rules also define 
2 categories of exemptions for INN prescribing: INN groups where 
the first choice of treatment should be continued throughout the 
therapy period (NO SWITCH) and medicinal product groups not 
suitable for INN prescribing (NO INN).
Conclusion: Operationalizing INN prescribing for electronic pre-
scribing was a difficult yet feasible assignment. The INN prescribing 
project resulted into universally applicable operational rules and a 
corresponding classification of the therapeutic arsenal and reference 
database. These outcomes can be used by other countries planning 
to implement electronic INN prescribing.
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Introduction: Traditionally, the training in clinical pharmacology 
concentrated primarily on teaching of rational drug application for 
students and clinical therapists. Clinical medicines development is 
another important field of clinical pharmacology that requires a 
different training approach closely following the emergence of new 
scientific knowledge.
Results: A modern life-long learning concept for clinical pharma-
cologists must take into consideration the emerging new technologies 
of medicines development and application. The appearance of highly 
sensitive and noninvasive technologies to measure pharmacokinetic 
and pharmacodynamic parameters makes possible drug investigation 
in humans using extremely low doses without substantial danger for 
the volunteers at the very early stage of medicines development. These 
so-called Phase 0 trials permit to enrich the animal results with human 
pharmacologic data before initiating the classical human Phase I dose 
escalation study requiring more extensive animal toxicology. In early 
clinical development of new types of biological medicinal agents, 
drug-containing nanoparticles, medical device and drug combina-
tions, new pharmaceutical formulations routinely require a team of 
clinicians and natural scientists to perform jointly the complex tasks 
of the early learning phase of clinical medicines development. Beside 
profound knowledge in their primary clinical specialty, the new gen-
eration of clinical pharmacologists needs extensive additional train-
ing in the new methodologies of drug discovery, molecular biology, 
immunology, translational medicine, etc. for efficiently functioning 
in a multidisciplinary team.
Conclusion: At the Semmelweis University, the teaching of a reor-
ganized postgraduate training plan for clinical pharmacologists was 
initiated applying the principles outlined above. On the basis of our 
experience, an outline for a new national curriculum of clinical phar-
macology has been developed, which will be presented. The new 
plan takes over several topics and concepts worked out during the 
harmonization of pharmaceutical medicine education in Europe by 
PharmaTrain. A certain overlap in pharmaceutical medicinal and clini-
cal pharmacological curricula is desired, considering that the optimal 
clinical application of new types of medicines needs much more basic 
scientific knowledge than the use of traditional medicinal agents.
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Introduction: Drug manufacturers developed “evergreening strate-
gies” to compete with generic medication after patent termination. 
These include marketing of slightly modified follow-on drugs (slow-
release formulations, single isomer chiral molecules, active metabo-
lites, or structural analogues/combinations of original patented 
drugs) and offering high rebates to hospitals that use brand-name or 
evergreening drugs. The Geneva University Hospitals (HUG) and the 
Geneva community have different rules indeed. Drug prices are nego-
tiated and prescriptions restricted at HUG, while prices are fixed and 
prescriptions unrestricted in the community. We examine the impact 
of listing these drugs in the hospital-restrictive drug formulary (RDF) 
on the health care system as a whole (“spillover effect”).
Patients (or Materials) and Methods: We linked hospital and com-
munity pharmacy invoice office data in the Swiss canton of Geneva 
to calculate utilization of 8 follow-on drugs in defined daily doses 
between 2000 and 2008. This database includes > 73% of the total 
of insured patients. To examine the financial spillover effect, we cal-
culated a monthly follow-on drug market share in DDDs for medica-
tions prescribed by hospital physicians dispensed in the community 
(eg, at hospital discharge, in outpatient clinics) in comparison to 
drugs prescribed by physicians in the community. The spillover effect 
dynamic was analyzed under robust time series analysis using autore-
gressive integrated moving average (ARIMA) models.
